Edwards George, Seeley Anna, Carter Adam, Patrick Smith Maia, Cross Elizabeth LA, Hughes Kathryn, Van den Bruel Ann, Llewelyn Martin J, Verbakel Jan Y, Hayward Gail
NIHR Community Healthcare Medtech and IVD Cooperative, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Biomark Insights. 2023 Jan 23;18:11772719221144459. doi: 10.1177/11772719221144459. eCollection 2023.
Urinary tract infection (UTI) affects half of women at least once in their lifetime. Current diagnosis involves urinary dipstick and urine culture, yet both methods have modest diagnostic accuracy, and cannot support decision-making in patient populations with high prevalence of asymptomatic bacteriuria, such as older adults. Detecting biomarkers of host response in the urine of hosts has the potential to improve diagnosis.
To synthesise the evidence of the diagnostic accuracy of novel biomarkers for UTI, and of their ability to differentiate UTI from asymptomatic bacteriuria.
A systematic review.
We searched MEDLINE, EMBASE, CINAHL and Web of Science for studies of novel biomarkers for the diagnosis of UTI. We excluded studies assessing biomarkers included in urine dipsticks as these have been well described previously. We included studies of adult patients (≥16 years) with a suspected or confirmed urinary tract infection using microscopy and culture as the reference standard. We excluded studies using clinical signs and symptoms, or urine dipstick only as a reference standard. Quality appraisal was performed using QUADAS-2. We summarised our data using point estimates and data accuracy statistics.
We included 37 studies on 4009 adults measuring 66 biomarkers. Study quality was limited by case-control design and study size; only 4 included studies had a prospective cohort design. IL-6 and IL-8 were the most studied biomarkers. We found plausible evidence to suggest that IL-8, IL-6, GRO-a, sTNF-1, sTNF-2 and MCR may benefit from more rigorous evaluation of their potential diagnostic value for UTI.
There is insufficient evidence to recommend the use of any novel biomarker for UTI diagnosis at present. Further evaluation of the more promising candidates, is needed before they can be recommended for clinical use.
尿路感染(UTI)在女性一生中至少影响半数女性。目前的诊断方法包括尿试纸检测和尿培养,但这两种方法的诊断准确性一般,且无法为无症状菌尿症高发人群(如老年人)的决策提供支持。检测宿主尿液中宿主反应的生物标志物有可能改善诊断。
综合新型生物标志物对UTI诊断准确性及其区分UTI与无症状菌尿症能力的证据。
系统评价。
我们检索了MEDLINE、EMBASE、CINAHL和科学网,以查找关于UTI诊断新型生物标志物的研究。我们排除了评估尿试纸中包含的生物标志物的研究,因为这些已在之前得到充分描述。我们纳入了以显微镜检查和培养作为参考标准的疑似或确诊尿路感染的成年患者(≥16岁)的研究。我们排除了仅使用临床体征和症状或尿试纸作为参考标准的研究。使用QUADAS-2进行质量评估。我们使用点估计和数据准确性统计来汇总数据。
我们纳入了37项针对4009名成年人测量66种生物标志物的研究。研究质量受病例对照设计和研究规模的限制;只有4项纳入研究采用了前瞻性队列设计。白细胞介素-6(IL-6)和白细胞介素-8(IL-8)是研究最多的生物标志物。我们发现有合理证据表明,白细胞介素-8、白细胞介素-6、生长调节致癌基因-α(GRO-α)、可溶性肿瘤坏死因子-1(sTNF-1)、可溶性肿瘤坏死因子-2(sTNF-2)和甘露糖结合凝集素受体(MCR)可能需要对其UTI潜在诊断价值进行更严格的评估。
目前没有足够的证据推荐使用任何新型生物标志物进行UTI诊断。在推荐更有前景的候选生物标志物用于临床使用之前,需要对其进行进一步评估。